| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H17N9O5S3 |
| Molecular Weight | 511.558 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4
InChI
InChIKey=HJJDBAOLQAWBMH-YCRCPZNHSA-N
InChI=1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1
Cefmenoxime is a semisynthetic beta-lactam cephalosporin antibiotic with activity similar to that of cefotaxime. Like other 'third-generation' cephalosporins it is active in vitro against most common Gram-positive and Gram-negative pathogens, is a potent inhibitor of Enterobacteriaceae (including beta-lactamase-producing strains), and is resistant to hydrolysis by beta-lactamases. Cefmenoxime has a high rate of clinical efficacy in many types of infection and is at least equal in clinical and bacteriological efficacy to several other cephalosporins in urinary tract infections, respiratory tract infections, postoperative infections and gonorrhoea. The bactericidal activity of cefmenoxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefmenoxime is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases. Cefmenoxime is marketed in Japan under the brand name Bestron, indicated for the treatment of otitis externa, otitis media, and sinusitis. Cefmenoxime hydrochloride was approved by the U.S. Food and Drug Administration (FDA) on Dec 30, 1987. It was developed and marketed as Cefmax®, but it has being discontinued.
Originator
Approval Year
Doses
Sourcing
PubMed
Sample Use Guides
Dissolve the powder in the attached solvent at a final
concentration of 10 mg (potency)/1 mL as cefmenoxime
hydrochloride, and used as follows:
For otitis externa and otitis media, usually instill 6 to 10 drops
into the ear and keep the same position for about 10 minutes
twice daily.
For sinusitis, usually inhale nasally by a nebulizer 2 to 4 mL
every other day, 3 times per week or inject 1 mL into the
maxillary sinus once per week.
The frequency of administration may be adjusted depending
on the patient’s symptoms.
Route of Administration:
Topical
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
